Inhibrx Biosciences (INBX) Liabilities and Shareholders Equity (2023 - 2026)

Inhibrx Biosciences (INBX) has reported Liabilities and Shareholders Equity for 3 consecutive years, with $146.5 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Liabilities and Shareholders Equity fell 18.97% year-over-year to $146.5 million; the TTM figure through Dec 2025 stood at $778.7 million (up 17.67% YoY), while the FY2025 annual figure was $146.5 million, down 18.97% from the prior year.
• Liabilities and Shareholders Equity slipped to $146.5 million in Q4 2025 per INBX's latest filing, from $177.5 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $307.9 million in Q4 2023 and bottomed at $146.5 million in Q4 2025.
• Historically, Liabilities and Shareholders Equity has averaged $218.5 million across 3 years, with a median of $217.3 million in 2024.
• Annual changes were most pronounced in 2024 — Liabilities and Shareholders Equity plunged 41.29% — and 2025, when it retreated 17.92%.
• Inhibrx Biosciences' Liabilities and Shareholders Equity stood at $307.9 million in 2023, then tumbled by 41.29% to $180.8 million in 2024, then retreated by 18.97% to $146.5 million in 2025.
• Business Quant data shows INBX's Liabilities and Shareholders Equity at $146.5 million in Q4 2025, $177.5 million in Q3 2025, and $212.1 million in Q2 2025.